RAYZEBIO INC (RYZB) Stock Price & Overview
NASDAQ:RYZB • US75525N1072
Current stock price
The current stock price of RYZB is 62.49 USD. Today RYZB is up by 0.02%. In the past month the price increased by 0.66%.
RYZB Key Statistics
- Market Cap
- 3.814B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.32
- Dividend Yield
- N/A
RYZB Stock Performance
RYZB Stock Chart
RYZB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RYZB.
RYZB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RYZB. While RYZB has a great health rating, there are worries on its profitability.
RYZB Earnings
RYZB Forecast & Estimates
11 analysts have analysed RYZB and the average price target is 54.4 USD. This implies a price decrease of -12.95% is expected in the next year compared to the current price of 62.49.
RYZB Groups
Sector & Classification
RYZB Financial Highlights
Over the last trailing twelve months RYZB reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS decreased by -29.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.12% | ||
| ROE | -12.71% | ||
| Debt/Equity | 0 |
RYZB Ownership
RYZB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 365.196B | ||
| AMGN | AMGEN INC | 15.32 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 10.94 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.34 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RYZB
Company Profile
RayzeBio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California. The company went IPO on 2023-09-15. RayzeBio, Inc. is a vertically integrated radiopharmaceutical therapeutics company. The firm is focused on building a somatostatin receptor type 2 (SSTR2) franchise. The firm's drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing SSTR2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225, an alpha particle radioisotope. In addition to its SSTR2 franchise, the Company has discovered a peptide that selectively binds to Glypican-3 (GPC3), an oncofetal protein selectively overexpressed in hepatocellular carcinoma (HCC) as well as other cancers. The firm is enrolled in a registrational Phase III clinical trial of RYZ101 for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs) in patients who have experienced progression of their cancer following treatment with Lu177 therapy.
Company Info
IPO: 2023-09-15
RAYZEBIO INC
5505 Morehouse Drive, Suite 300
San Diego CALIFORNIA US
Employees: 88
Phone: 16199372754
RAYZEBIO INC / RYZB FAQ
Can you describe the business of RAYZEBIO INC?
RayzeBio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California. The company went IPO on 2023-09-15. RayzeBio, Inc. is a vertically integrated radiopharmaceutical therapeutics company. The firm is focused on building a somatostatin receptor type 2 (SSTR2) franchise. The firm's drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing SSTR2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225, an alpha particle radioisotope. In addition to its SSTR2 franchise, the Company has discovered a peptide that selectively binds to Glypican-3 (GPC3), an oncofetal protein selectively overexpressed in hepatocellular carcinoma (HCC) as well as other cancers. The firm is enrolled in a registrational Phase III clinical trial of RYZ101 for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs) in patients who have experienced progression of their cancer following treatment with Lu177 therapy.
What is the stock price of RAYZEBIO INC today?
The current stock price of RYZB is 62.49 USD. The price increased by 0.02% in the last trading session.
Does RAYZEBIO INC pay dividends?
RYZB does not pay a dividend.
How is the ChartMill rating for RAYZEBIO INC?
RYZB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy RYZB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RYZB.
Can you provide the number of employees for RAYZEBIO INC?
RAYZEBIO INC (RYZB) currently has 88 employees.
What is the ownership structure of RAYZEBIO INC (RYZB)?
You can find the ownership structure of RAYZEBIO INC (RYZB) on the Ownership tab.